Skip to main content

Table 3 Treatment effect on cytokines, chemokines, metalloproteinases and growth factors a

From: A pilot open-label trial of minocycline in patients with autism and regressive features

Analyte Cerebrospinal fluid (CSF) Serum Plasma
Z P Z P Z P
TNFα −0.45 0.66 −1.78 0.074  
IL-6 −0.36 0.72 −1.75 0.08
CCL2 (MCP-1) −1.78 0.075 −1.27 0.24
CCL3 (MIP-1α) −0.18 0.86 −0.76 0.45
CCL5 (RANTES) −0.73 0.47 0.66 0.61
CXCL8 (IL-8) −0.45 0.66 −1.99 0.047
BDNFb −2.03 0.042   −0.76 0.45
Truncated-BDNF/α-2 Mc   −2.19 0.028  
Mature-BDNF/α-2 M c −0.87 0.386
CD40L −0.89 0.37   −1.33 0.18
GDNF −0.37 0.71 −1.83 0.07
HGF −2.19 0.028 −1.25 0.21
Leptin −1.48 0.14 −0.27 0.79
MMP-1   −1.07 0.29
MMP-3 −0.15 0.88
MMP-7 −1.89 0.059
MMP-8 −0.05 0.96
MMP-9 −1.38 0.17
  1. aSelected analytes, Mann–Whitney U-test.
  2. bQuantified by Luminex technique. In CSF only the truncated-BDNF form appears to be detectable in immunobotting experiments.
  3. cQuantified by immunoblotting and densitometry analysis. Significance was calculated based on ratio BDNF isoform/α-2 M.